2022
Proteasomal degradation within endocytic organelles can mediate antigen cross- presentation
Sengupta D, Graham M, Liu X, Cresswell P. Proteasomal degradation within endocytic organelles can mediate antigen cross- presentation. Molecular Immunology 2022, 150: 23. DOI: 10.1016/j.molimm.2022.05.080.Peer-Reviewed Original ResearchDendritic cellsMHC-I moleculesMouse bone marrow-derived dendritic cellsBone marrow-derived dendritic cellsMarrow-derived dendritic cellsAntigen processingConventional antigen processingMouse dendritic cellsMHC-I-peptide complexesSurface MHCMHCSurface expressionProteasome inhibitionPeptide loadingHuman B2Cell phagosomesCell typesActive proteasomesSpecific peptidesCellsPeptidesEndocytic compartmentsProteasomal degradationEndocytic pathway
2011
TAP-independent presentation of the melanoma vaccine candidate epitope gp100209-217 requires no gp100 sequences outside the core peptide and is sensitive to cytosolic TPP2 degradation (100.2)
Leonhardt R, Vigneron N, Van den Eynde B, Cresswell P. TAP-independent presentation of the melanoma vaccine candidate epitope gp100209-217 requires no gp100 sequences outside the core peptide and is sensitive to cytosolic TPP2 degradation (100.2). The Journal Of Immunology 2011, 186: 100.2-100.2. DOI: 10.4049/jimmunol.186.supp.100.2.Peer-Reviewed Original ResearchMHC class ITripeptidyl peptidase 2TAP-independent presentationClass ITumor-specific antigenic peptideImmune evasion strategiesPeptide vaccineAntigen presentationImmune evasionHLAEvasion strategiesAntigenic peptidesPeptidase 2Proteasome activityGp100PresentationTumorsTAP transporterTAP functionTransporter systemCore peptidePeptidesTotal lackVaccine
1997
Negative Regulation by HLA-DO of MHC Class II-Restricted Antigen Processing
Denzin L, Sant'Angelo D, Hammond C, Surman M, Cresswell P. Negative Regulation by HLA-DO of MHC Class II-Restricted Antigen Processing. Science 1997, 278: 106-109. PMID: 9311912, DOI: 10.1126/science.278.5335.106.Peer-Reviewed Original ResearchConceptsHLA-DOII-like moleculeAntigen processingClass IIHLA-DMMajor histocompatibility complex classMHC class IIHistocompatibility complex classClass II moleculesII-CLIP complexesHLA-DM functionT cell linesB cellsChain-derived peptideAntigenic peptidesImportant modulatorCell linesDM functionInvariant chain-derived peptidesComplex classNegative regulationPeptides
1994
Human transporters associated with antigen processing possess a promiscuous peptide-binding site
Androlewicz M, Cresswell P. Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity 1994, 1: 7-14. PMID: 7889401, DOI: 10.1016/1074-7613(94)90004-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphateAmino Acid SequenceAntigen PresentationATP Binding Cassette Transporter, Subfamily B, Member 2ATP-Binding Cassette TransportersBinding SitesBinding, CompetitiveBiological Transport, ActiveCarrier ProteinsCell LineHistocompatibility Antigens Class IHumansMolecular Sequence DataOligopeptidesAssembly, Transport, and Function of MHC Class II Molecules
Cresswell P. Assembly, Transport, and Function of MHC Class II Molecules. Annual Review Of Immunology 1994, 12: 259-291. PMID: 8011283, DOI: 10.1146/annurev.iy.12.040194.001355.Peer-Reviewed Original ResearchConceptsII-invariant chain complexesEndosomal systemMembrane protein transportTrans-Golgi networkCell surfaceChain complexesAdditional gene productsAlpha beta dimersLate endosome/Beta dimersProtein transportCytoplasmic tailGene productsConstitutive pathwayEndosome/Golgi apparatusEndoplasmic reticulumInvariant chainMHC class II moleculesPrimary functionPrecise mechanismClass II moleculesComplexesPeptidesBind peptidesAssembly and Transport of Class I MHC‐Peptide Complexes
Cresswell P, Androlewicz M, Ortmann B. Assembly and Transport of Class I MHC‐Peptide Complexes. Novartis Foundation Symposia 1994, 187: 150-169. PMID: 7796669, DOI: 10.1002/9780470514672.ch10.Peer-Reviewed Original ResearchConceptsTAP moleculesComplex moleculesPeptide derivativesMoleculesLonger peptidesClass I MHC-peptide complexesPeptide-binding siteComplexesClass I-peptide complexesPeptidesCompetition experimentsAssemblyAmino acidsDimersDerivativesClass I major histocompatibility complex moleculesWide rangeChainMHC-peptide complexesAcidTransportSurface
1992
HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides
Riberdy J, Newcomb J, Surman M, Barbosat J, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992, 360: 474-477. PMID: 1448172, DOI: 10.1038/360474a0.Peer-Reviewed Original ResearchConceptsClass II moleculesInvariant chainMajor histocompatibility complex (MHC) class II moleculesCell linesHLA-DR moleculesClass II binding siteInvariant chain peptideHLA-DR3 moleculesMore MHCClass IIAntigen processingT2 transfectantsAntigenic peptidesHuman cell linesChain peptideVivo conditionsPeptidesLarge proportionProteolytic cleavageMutant cell linesCertain human cell linesEarly stagesTransfectantsChemistry and functional role of the invariant chain
Cresswell P. Chemistry and functional role of the invariant chain. Current Opinion In Immunology 1992, 4: 87-92. PMID: 1317713, DOI: 10.1016/0952-7915(92)90131-w.Peer-Reviewed Original Research
1987
Immune recognition of human major histocompatibility antigens: localization by a comprehensive synthetic strategy of the continuous antigenic sites in the first domain of HLA‐DR2 β chain
Ulrich R, Atassi H, Lutz P, Cresswell P, Atassi M. Immune recognition of human major histocompatibility antigens: localization by a comprehensive synthetic strategy of the continuous antigenic sites in the first domain of HLA‐DR2 β chain. European Journal Of Immunology 1987, 17: 497-502. PMID: 2436923, DOI: 10.1002/eji.1830170410.Peer-Reviewed Original ResearchConceptsAntibody-binding activityHuman major histocompatibility antigensBeta chainMajor histocompatibility antigensAntigenic sitesHistocompatibility antigensImmune recognitionChain antiserumIsolated beta chainsMost antiseraAntiserumPeptide 81Continuous antigenic sitesΒ-chainPeptidesFirst domainHLAImmunodominanceAntigenComprehensive synthetic strategy